Commentary
- PMID: 39982833
- PMCID: PMC11908852
- DOI: 10.1093/schbul/sbae191
Commentary
Conflict of interest statement
RSEK receives consulting income from Kynexis, Merck, WCG, Boehringer Ingelheim, Neurocrine, Gedeon-Richter, Novartis, Vandria, Damona, and received royalties from the BACS and VRFCAT.
References
-
- Horan et al. This issue.
-
- Khalil H, Al Habbab T, Reuteman-Fowler C, Keefe RSE.. Investigational New Drugs for the Treatment of Cognitive Impairments of Schizophrenia: A Review of Trials. Poster presented at the Annual Meeting of the Psych Congress. Boston, Massachusetts; October 29–November 2, 2024.
-
- Keefe RSE, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A.. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophr Res. 2011;125:161–168. - PubMed
-
- Georgiades A, Davis VG, Atkins A, et al.Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients. Schizophr Res. 2017;190:172–179. - PubMed
-
- Dickinson D, Ramsey M, Gold JM.. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64:532. - PubMed
LinkOut - more resources
Full Text Sources
